AJCC stage at sampling was borderline associated with osteopontin levels (P=0.06; Table I) with a higher median level noted in patients with treated stage III melanomas compared to those with treated stage I–II disease (64.3 and 54.1 ng/ml, respectively). Here, SPP1 is linked to melanoma.